{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:30:08Z","timestamp":1785281408641,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the State Key Laboratory of Dampness Syndrome of Chinese Medicine","award":["SZ2021ZZ43"],"award-info":[{"award-number":["SZ2021ZZ43"]}]},{"name":"Zhang Daning\u2019s Academic Experience Inheritance Studio, Guangdong Provincial Hospital of Traditional Chinese Medicine","award":["E43714"],"award-info":[{"award-number":["E43714"]}]},{"name":"Yang Nizhi's Inheritance Studio of Renowned Traditional Chinese Medicine Practitioners Nationwide, established by the National Administration of Traditional Chinese Medicine","award":["[2016] No. 167"],"award-info":[{"award-number":["[2016] No. 167"]}]},{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","award":["20232051"],"award-info":[{"award-number":["20232051"]}],"id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04385-9","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:14:29Z","timestamp":1754709269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bevacizumab-associated glomerular microangiopathy: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Rui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-zhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"issue":"5","key":"4385_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega MDLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684\u2013700. https:\/\/doi.org\/10.1038\/s41379-018-0186-4.","journal-title":"Mod Pathol"},{"issue":"11","key":"4385_CR2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10157-021-02090-z","volume":"25","author":"M Ozawa","year":"2021","unstructured":"Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. Clin Exp Nephrol. 2021;25(11):1193\u2013202. https:\/\/doi.org\/10.1007\/s10157-021-02090-z.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4385_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13730-020-00504-7","volume":"10","author":"M Morimoto","year":"2021","unstructured":"Morimoto M, Arai T, Matsuura M, Ono Y. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer. Cen Case Rep. 2021;10(1):6\u201311. https:\/\/doi.org\/10.1007\/s13730-020-00504-7.","journal-title":"Cen Case Rep"},{"issue":"5","key":"4385_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ki.2015.30","volume":"87","author":"MA Perazella","year":"2015","unstructured":"Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87(5):909\u201317. https:\/\/doi.org\/10.1038\/ki.2015.30.","journal-title":"Kidney Int"},{"issue":"2","key":"4385_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic Inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrology: Jasn. 2019;30(2):187\u2013200, 2018080853. PubMed PMID: 30642877IF: 9.4 Q1 B1.","journal-title":"J Am Soc Nephrology: Jasn"},{"key":"4385_CR6","doi-asserted-by":"publisher","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (Vascular endothelial growth factor) Inhibitor\u2013Associated hypertension and vascular disease. Hypertension. 2018;71(2). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10271","DOI":"10.1161\/HYPERTENSIONAHA.117.10271"},{"issue":"1","key":"4385_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest. 2017;127(1):199\u2013214. https:\/\/doi.org\/10.1172\/JCI86418.","journal-title":"J Clin Invest"},{"issue":"2","key":"4385_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","volume":"29","author":"C Vigneau","year":"2014","unstructured":"Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, et al. All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a rare study. Nephrol Dial Transpl. 2014;29(2):325\u201332. https:\/\/doi.org\/10.1093\/ndt\/gft465.","journal-title":"Nephrol Dial Transpl"},{"key":"4385_CR9","unstructured":"Vera E, Ashley J, Jolanta J, Howard K, Mark H, Joseph H. W, VEGF Inhibition and renal thrombotic microangiopathy. New Engl J Med 2008."},{"issue":"6","key":"4385_CR10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner Herold M. Characteristic morphological changes in anti-VEGF therapy\u2010induced glomerular microangiopathy. Histopathology. 2018;73(6):990\u20131001. https:\/\/doi.org\/10.1111\/his.13716.","journal-title":"Histopathology"},{"issue":"2","key":"4385_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41416-019-0481-y","volume":"121","author":"C Plummer","year":"2019","unstructured":"Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Brit J Cancer. 2019;121(2):109\u201316. https:\/\/doi.org\/10.1038\/s41416-019-0481-y.","journal-title":"Brit J Cancer"},{"issue":"7","key":"4385_CR12","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ekir.2024.04.022","volume":"9","author":"M Martin","year":"2024","unstructured":"Martin M, Llorens-Cebria C, Le\u00f3n-Rom\u00e1n J, Perurena-Prieto J, Perez-Beltran V, Saumell S, et al. Ex vivo C5b-9 deposition test to monitor complement activity in clinical and subclinical atypical hemolytic uremic syndrome and in Transplantation-Associated thrombotic microangiopathy. Kidney Int Rep. 2024;9(7):2227\u201339. https:\/\/doi.org\/10.1016\/j.ekir.2024.04.022.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4385_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/23993693221131584","volume":"7","author":"V Srinivasan","year":"2023","unstructured":"Srinivasan V, Kfoury B, Ahmad S, Cohen J, Geara AS. Long term outcomes of bevacizumab-associated kidney adverse effects. J Onco-Nephrology. 2023;7(1):6\u201310. https:\/\/doi.org\/10.1177\/23993693221131584.","journal-title":"J Onco-Nephrology"},{"issue":"6","key":"4385_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.amjms.2023.09.005","volume":"366","author":"J Li","year":"2023","unstructured":"Li J, Li X, Li C. Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney. Am J Med Sci. 2023;366(6):404\u201312. https:\/\/doi.org\/10.1016\/j.amjms.2023.09.005.","journal-title":"Am J Med Sci"},{"issue":"1","key":"4385_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/CN110443","volume":"96","author":"R Hilburg","year":"2021","unstructured":"Hilburg R, Geara AS, Qiu MK, Palmer MB, Chiang EY, Burger RA, et al. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case series and systematic review of the literature. Cn. 2021;96(1):51\u20139. https:\/\/doi.org\/10.5414\/CN110443","journal-title":"Cn"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04385-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:17:10Z","timestamp":1757359030000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04385-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04385-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (approval number: 2024-20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the participant included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication has been obtained from the individual included in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}